Terms: = Head and neck cancer AND ATR, Q13535, 545, ENSG00000175054, MEC1, SCKL, SCKL1, FRP1 AND Treatment
135 results:
1. Comparison of mutation landscapes of pretreatment versus recurrent squamous cell carcinoma of the oral cavity: The possible mechanism of resistance to standard treatment.
Payungwong T; Angkulkrerkkrai K; Chaiboonchoe A; Lausoontornsiri W; Jirawatnotai S; Chindavijak S
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2004. PubMed ID: 38477073
[TBL] [Abstract] [Full Text] [Related]
2. ThermomiR-377-3p-induced suppression of Cirbp expression is required for effective elimination of cancer cells and cancer stem-like cells by hyperthermia.
Lin TY; Jia JS; Luo WR; Lin XL; Xiao SJ; Yang J; Xia JW; Zhou C; Zhou ZH; Lin SJ; Li QW; Yang ZZ; Lei Y; Yang WQ; Shen HF; Huang SH; Wang SC; Chen LB; Yang YL; Xue SW; Li YL; Dai GQ; Zhou Y; Li YC; Wei F; Rong XX; Luo XJ; Zhao BX; Huang WH; Xiao D; Sun Y
J Exp Clin Cancer Res; 2024 Feb; 43(1):62. PubMed ID: 38419081
[TBL] [Abstract] [Full Text] [Related]
3. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
Besse B; Pons-Tostivint E; Park K; Hartl S; Forde PM; Hochmair MJ; Awad MM; Thomas M; Goss G; Wheatley-Price P; Shepherd FA; Florescu M; Cheema P; Chu QSC; Kim SW; Morgensztern D; Johnson ML; Cousin S; Kim DW; Moskovitz MT; Vicente D; Aronson B; Hobson R; Ambrose HJ; Khosla S; Reddy A; Russell DL; Keddar MR; Conway JP; Barrett JC; Dean E; Kumar R; Dressman M; Jewsbury PJ; Iyer S; Barry ST; Cosaert J; Heymach JV
Nat Med; 2024 Mar; 30(3):716-729. PubMed ID: 38351187
[TBL] [Abstract] [Full Text] [Related]
4. Esophageal cancer in octogenarians: Should esophagectomy be done?
Cooper L; Orgad R; Levi Y; Shmilovitch H; Feferman Y; Solomon D; Kashtan H
J Geriatr Oncol; 2024 Mar; 15(2):101710. PubMed ID: 38281389
[TBL] [Abstract] [Full Text] [Related]
5. The Interaction between CLSPN Gene Polymorphisms and Alcohol Consumption Contributes to Oral cancer Progression.
Hsieh MJ; Lo YS; Ho HY; Lin CC; Chuang YC; Chen MK
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256171
[TBL] [Abstract] [Full Text] [Related]
6. CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method.
Javed SR; Lord S; El Badri S; Harman R; Holmes J; Kamzi F; Maughan T; McIntosh D; Mukherjee S; Ooms A; Radhakrishna G; Shaw P; Hawkins MA
Br J Cancer; 2024 Feb; 130(3):467-475. PubMed ID: 38129525
[TBL] [Abstract] [Full Text] [Related]
7. Preclinical Evaluation of the atr Inhibitor BAY 1895344 as a Radiosensitizer for head and neck Squamous Cell Carcinoma.
Odhiambo DA; Pittman AN; Rickard AG; Castillo RJ; Bassil AM; Chen J; Ravotti ML; Xu ES; Himes JE; Daniel AR; Watts TL; Williams NT; Luo L; Kirsch DG; Mowery YM
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1315-1327. PubMed ID: 38104870
[TBL] [Abstract] [Full Text] [Related]
8. The atr inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines.
Schnoell J; Sparr C; Al-Gboore S; Haas M; Brkic FF; Kadletz-Wanke L; Heiduschka G; Jank BJ
Invest New Drugs; 2023 Dec; 41(6):842-850. PubMed ID: 37934325
[TBL] [Abstract] [Full Text] [Related]
9. Therapeutic inhibition of atr in differentiated thyroid cancer.
Lin SF; Lee YY; Wu MH; Lu YL; Yeh CN; Chen WY; Chou TC; Wong RJ
Endocr Relat Cancer; 2023 Dec; 30(12):. PubMed ID: 37902083
[TBL] [Abstract] [Full Text] [Related]
10. The cGAS/STING/IFN-1 Response in Squamous head and neck cancer Cells after Genotoxic Challenges and Abrogation of the atr-Chk1 and Fanconi Anemia Axis.
Zahnreich S; El Guerzyfy S; Kaufmann J; Schmidberger H
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834346
[TBL] [Abstract] [Full Text] [Related]
11. TPP1 Inhibits DNA Damage Response and Chemosensitivity in Esophageal cancer.
Wen J; Zhong X; Gao C; Yang M; Tang M; Yuan Z; Wang Q; Xu L; Ma Q; Guo X; Fang L
Crit Rev Eukaryot Gene Expr; 2023; 33(8):77-91. PubMed ID: 37606165
[TBL] [Abstract] [Full Text] [Related]
12. Endoscopic hemithyroidectomy plus prophylactic central neck dissection via breast approach versus gasless transaxillary approach in treating low-risk papillary thyroid cancer: a retrospective series.
Zhang X; Hu XJ; Hua KJ
Updates Surg; 2023 Apr; 75(3):707-715. PubMed ID: 36848003
[TBL] [Abstract] [Full Text] [Related]
13. VE-822 Enhanced Cisplatin Chemotherapy Effects on head and neck Squamous Cell Carcinoma Drug-resistant Cells.
Chen T; Yang F; Dai X; Yu Y; Sun Y; Wu X; Li R; Zhou Q
Curr Cancer Drug Targets; 2023; 23(6):482-495. PubMed ID: 36748213
[TBL] [Abstract] [Full Text] [Related]
14. Establishment of Mucoepidermoid Carcinoma Cell Lines from Surgical and Recurrence Biopsy Specimens.
Yamanaka S; Suzuki S; Ito H; Sivasundaram K; Hanamura I; Okubo I; Yoshikawa K; Ono S; Takahara T; Satou A; Tsuzuki T; Ueda R; Ogawa T; Fujimoto Y
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675234
[TBL] [Abstract] [Full Text] [Related]
15. Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control.
Concannon K; Morris BB; Gay CM; Byers LA
Mol Cell; 2023 Mar; 83(5):660-680. PubMed ID: 36669489
[TBL] [Abstract] [Full Text] [Related]
16. Thyroid dysfunction in Chinese nasopharyngeal carcinoma after anti-PD-1 therapy and its association with treatment response.
Chen ZH; Zheng WH; Wu CF; Kou J; Yang XL; Lin L; Lv JW; Sun Y; Zhou GQ
BMC Med; 2023 Jan; 21(1):18. PubMed ID: 36647058
[TBL] [Abstract] [Full Text] [Related]
17. Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States.
Hu J; Ye Z; Xu Z; Hao Z; Wang Y
Front Public Health; 2022; 10():941738. PubMed ID: 36568792
[TBL] [Abstract] [Full Text] [Related]
18. ARPC1B promotes mesenchymal phenotype maintenance and radiotherapy resistance by blocking TRIM21-mediated degradation of IFI16 and HuR in glioma stem cells.
Gao Z; Xu J; Fan Y; Zhang Z; Wang H; Qian M; Zhang P; Deng L; Shen J; Xue H; Zhao R; Zhou T; Guo X; Li G
J Exp Clin Cancer Res; 2022 Nov; 41(1):323. PubMed ID: 36380368
[TBL] [Abstract] [Full Text] [Related]
19. Low-Dose Immunotherapy in head and neck cancer: A Randomized Study.
Patil VM; Noronha V; Menon N; Rai R; Bhattacharjee A; Singh A; Nawale K; Jogdhankar S; Tambe R; Dhumal S; Sawant R; Alone M; Karla D; Peelay Z; Pathak S; Balaji A; Kumar S; Purandare N; Agarwal A; Puranik A; Mahajan A; Janu A; Kumar Singh G; Mittal N; Yadav S; Banavali S; Prabhash K
J Clin Oncol; 2023 Jan; 41(2):222-232. PubMed ID: 36265101
[TBL] [Abstract] [Full Text] [Related]
20. Predictive Factors for Bilateral Disease in Papillary Microcarcinoma: A Retrospective Cohort Study.
Lindner K; Iwen KA; Kußmann J; Fendrich V
Curr Oncol; 2022 Aug; 29(9):6010-6017. PubMed ID: 36135042
[TBL] [Abstract] [Full Text] [Related]
[Next]
